BioSpace News Archive

Patients who took Taltz in the post-marketing study achieved higher rates of “complete skin clearance” in comparison to Tremfya as measured by PASI 100.

Today it was announced that the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ prefilled syringes for Eylea.

Deciphera’s stock jumped from Monday’s close of $19.95 to $44.40 this morning after the company showed ripretinib provided 6.3 months of progression-free survival compared to one month from placebo.

A mentor is a person who has the professional experience to provide meaningful insight applicable to your situation.

Osteoporosis is a disease where the bones become more porous and fragile, which dramatically increases the risk of bone fractures. It affects about 200 million people worldwide, is a progressive disease, and there are often are no symptoms until a fracture.

LGC announced the acquisition of a majority stake in Toronto Research Chemicals, a leading manufacturer and supplier of synthetic organic bio-chemicals which are used as reference standards, research tools and building blocks by a highly diversified global customer base across the pharmaceutical, applied and research sectors.

Pharming Group N.V. announced it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome.

Pulmocide Ltd is pleased to announce that in vitro data published in the Journal of Antimicrobial Chemotherapy highlight the potential of its novel antifungal candidate PC945 in the treatment of Candida auris.

Under the terms of the deal with Yale University, Yale researchers led by Geoff Chupp will conduct discovery research on targets associated with pulmonary diseases, then turn over the candidates to CureVac for preclinical and clinical development.

Jack Bailey, head of the company’s U.S. pharmaceuticals business is stepping down at the end of the year.